Tear cytokine levels in vernal keratoconjunctivitis: The effect of topical 0.05% cyclosporine a therapy

Cornea

Volumn 32, Issue 8, 2013, Pages 1149-1154

  Oray, Merih ^a   Toker, Ebru ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

cyclosporine A; cytokines; tear cytokines; vernal keratoconjunctivitis

Indexed keywords

CYCLOSPORIN A; CYTOKINE; EOTAXIN; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CELL FREE SYSTEM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MEDIATOR; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SERUM; SUPERNATANT; SYMPTOM; TEAR FILM; TREATMENT DURATION; VERNAL CONJUNCTIVITIS;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CHILD; CONJUNCTIVITIS, ALLERGIC; CYCLOSPORINE; CYTOKINES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKINS; MALE; PROSPECTIVE STUDIES; TEARS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84880573180     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31828ffdf8     Document Type: Article

References (35)

1. Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res. 2002;21:319-339.
2. Kumar S. Vernal keratoconjunctivitis: a major review. Acta Ophthalmol. 2009;87:133-147.
3. Solomon A. Advances in ocular allergy: basic mechanisms, clinical patterns and new therapies. Curr Opin Allergy Clin Immunol. 2001;1:477-482.
4. Fujishima H, Shimazaki J, Takeuchi T, et al. Interleukin-4 and IgE in seasonal allergic conjunctivitis. Ophthalmologica. 1996;210:325-328.
5. McGill J. Conjunctival cytokines in ocular allergy. Clin Exp Allergy. 2000;30:1355-1357.
6. McGill JI, Holgate ST, Church MK, et al. Allergic eye disease mechanisms. Br J Ophthalmol. 1998;82:1203-1214.
7. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54:321-338.
8. Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology. 2004;111:476-482.
9. Cook EB, Stahl JL, Lowe L. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytom-etry: allergics vs. non-allergics. J Immunol Methods. 2001;254:109-118.
10. BenEzra D, Pe'er J, Brodsky M, et al. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol. 1986; 101:278-282.
11. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol. 1990;110: 641-645.
12. Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjuncti- vitis. Ophthalmology. 1991;98:1679-1684.
13. Spadavecchia L, Fanelli P, Tesse R, et al. Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol. 2006;17:527-532.
14. Gupta V, Sahu PK. Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye (Lond). 2001;15:39-41.
15. Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclo-sporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2002;89:298-303.
16. Ozcan AA, Ersoz TR, Dulger E. Management of severe allergic conjunctivitis with topical cyclosporin A 0.05% eyedrops. Cornea. 2007;26: 1035-1038.
17. Cook EB. Tear cytokines in acute and chronic ocular allergic inflammation. Curr Opin Allergy Clin Immunol. 2004;4:441-445.
18. Leonardi A, Curnow SJ, Zhan H, et al. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunc-tival fibroblast cultures. Clin Exp Allergy. 2006;36:774-784.
19. Nivenius E, Montan PG, Chryssanthou E. No apparent association between periocular and ocular microcolonization and the degree of inflammation in patients with atopic keratoconjunctivitis. Clin Exp Allergy. 2004;34:725-730.
20. Leonardi A, DeFranchis G, Zancanaro F, et al. Identification of local Th2 and Th0 lymphocytes in vernal conjunctivitis by cytokine flow cytom-etry. Invest Ophthalmol Vis Sci. 1999;40:3036-3040.
21. Leonardi A, Fregona IA, Plebani M, et al. Th1-and Th2-type cytokines in chronic ocular allergy. Graefes Arch Clin Exp Ophthalmol. 2006;244: 1240-1245.
22. Nelson DL, Rubin LA, Kurman CC, et al. An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol. 1986;6:114-120.
23. Trocme SD, Kephart GM, Allansmith MR, et al. Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis. Am J Ophthal-mol. 1989;108:57-63.
24. Rankin SM, Conroy DM, Williams TJ. Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today. 2000; 6:20-27.
25. Hingorani M, Calder V, Jolly G, et al. Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases. J Allergy Clin Immunol. 1998;102:821-830.
26. Uchio E, Ono SY, Ikezawa Z, et al. Tear levels of interferon-gamma, interleukin (IL)-2, IL-4 and IL-5 in patients with vernal keratoconjunc-tivitis, atopic keratoconjunctivitis and allergic conjunctivitis. Clin Exp Allergy. 2000;30:103-109.
27. Fukagawa K, Nakajima T, Tsubota K, et al. Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage. J Allergy Clin Immunol. 1999;103:1220-1221.
28. Leonardi A, Sathe S, Bortolotti M, et al. Cytokines, matrix metallopro-teases, angiogenic and growth factors in tears of normal subjects and vernal keratoconjunctivitis patients. Allergy. 2009;64:710-717.
29. Leonardi A, Borghesan F, DePaoli M, et al. Procollagens and inflammatory cytokine concentrations in tarsal and limbal vernal keratoconjuncti-vitis. Exp Eye Res. 1998;67:105-112.
30. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-1132.
31. Wong CK, Ho CY, Ko FW. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol. 2001;125:177-183.
32. Soroosh P, Doherty TA. Th9 and allergic disease. Immunology. 2009; 127:450-458.
33. Erpenbeck VJ, Hohlfeld JM, Discher M, et al. Increased expression of interleukin-9 messenger RNA after segmental allergen challenge in allergic asthmatics. Chest. 2003;123(3 suppl):370S.
34. Power WJ, Mullaney P, Farrell M, et al. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjögren's syndrome. Cornea. 1993;12:507-511.
35. Holland EJ, Chan CC, Kuwabara T. Immunohistologic findings and results of treatment with cyclosporine in ligneous conjunctivitis. Am J Ophthalmol. 1989;107:160-166.